دورية أكاديمية
NOD2, CD14 and TLR4 mutations do not influence response to adalimumab in patients with Crohn's disease: a preliminary report Las mutaciones de NOD2, CD14 y TLR4 no influyen sobre la respuesta al adalimumab en pacientes con enfermedad de Crohn: informe preliminar
| العنوان: | NOD2, CD14 and TLR4 mutations do not influence response to adalimumab in patients with Crohn's disease: a preliminary report Las mutaciones de NOD2, CD14 y TLR4 no influyen sobre la respuesta al adalimumab en pacientes con enfermedad de Crohn: informe preliminar |
|---|---|
| المؤلفون: | M. Barreiro-de Acosta, S. Ouburg, S. A. Morré, J. B. A. Crusius, A. Lorenzo, J. Potel, A. S. Peña, J. E. Domínguez-Muñoz |
| المصدر: | Revista Espanola de Enfermedades Digestivas, Vol 102, Iss 10, Pp 591-595 (2010) |
| بيانات النشر: | Aran Ediciones, 2010. |
| سنة النشر: | 2010 |
| المجموعة: | LCC:Diseases of the digestive system. Gastroenterology |
| مصطلحات موضوعية: | Crohn's disease, Genotypes, Adalimumab, Diseases of the digestive system. Gastroenterology, RC799-869 |
| الوصف: | Introduction: adalimumab is a recombinant fully-human monoclonal immunoglobulin (IgG1) antibody utilized in the treatment of Crohn's disease. Unfortunately no clinical or genetic markers exist to predict response to anti-tumor necrosis factor-alpha (TNF) therapy. The aim of this study was to evaluate the association between selected genes involved in cytokine regulation and response to adalimumab treatment in Crohn's disease. Methods: twenty-four patients with Crohn's disease either naïve (n = 8) or had lost response or were unable to tolerate the chimeric anti-TNF antibody infliximab (n=16) were enrolled in the study. Patients were genotyped for main polymorphisms in NOD2, CD14 and TLR4 genes. Response to adalimumab treatment was defined as a decrease of Crohn's disease activity index of at least 100 points or a closure of at least 50% of fistulas in case of fistulizing Crohn's disease. Results: overall, 75% of patients did respond to treatment. However, no statistically significant association was found between any of the genotypes and the response to adalimumab. Conclusions: in our small study group no association between the studied polymorphisms and response to adalimumab was apparent. Systematic studies to search for genetic markers of response to anti-TNF therapy are necessary. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English Spanish; Castilian |
| تدمد: | 1130-0108 |
| Relation: | http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082010001000005; https://doaj.org/toc/1130-0108 |
| URL الوصول: | https://doaj.org/article/cff43b96e8164e9fbbf5862185cbdf67 |
| رقم الأكسشن: | edsdoj.ff43b96e8164e9fbbf5862185cbdf67 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 11300108 |
|---|